Guangdong Zhongsheng’s RAY1225 Receives NMPA Approval for Clinical Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received approval...
Drug
Vcanbio’s VUM02 Gains CDE Review for Liver Failure and ARDS Clinical Trials
Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that two additional clinical...
Luye Pharma’s Biosimilar BA9101 Completes Phase III Study Enrollment with Ocumension
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has completed...
Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...
CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...
Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan
Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...
Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806
Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...
CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine
China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...
CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting
China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...
Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing
France-based Inventiva S.A. and China’s Chia Tai Tianqing have successfully filed a clinical trial application...
Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
AusperBio and Asymchem Form Strategic Partnership for Drug Development
China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...
Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...
Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma
Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
Inventiva and Chia Tai Tianqing File Clinical Trial for Lanifibranor with CDE
France-based Inventiva S.A. and China’s Chia Tai Tianqing have filed a clinical trial application with...
Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...
Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma
Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...